Table 3.

Other Ongoing Combined Therapies for HCC

Trial NCT number	Intervention	Phase	State	Characteristic
NCT04642547	Lenvatinib+Gefitinib	I Single arm	Recruiting	Lenvatinib-resistant
NCT04911959	Lenvatinib+TACE vs. □ TACE	I	Not yet recruiting	MVI-positive HCC
NCT05042336	Camrelizumab+Lenvatinib + TACE	Ib/II Single arm	Not yet recruiting	Borderline resectable HCC
NCT05185739	Pembrolizumab vs. □ Lenvatinib vs. □ Pembrolizumab+ Lenvatinib	II triple arm	Not yet recruiting	Resectable HCC
NCT04425226	Pembrolizumab+ Lenvatinib	I	Recruiting	Before liver transplant
NCT05103904	Lenvatinib	II	Recruiting	Recurrence after liver transplantation

Abbreviations: MVI, Microvascular invasion; TACE, Transarterial chemoembolization.